Patents Assigned to APTAHEM AB
  • Nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties
    Patent number: 11110115
    Abstract: The invention relates to a nucleic acid molecule or a composition comprising said molecule for use as an anti-inflammatory and/or anti-coagulant and/or organ-protective medicament. The invention also relates to a use of said nucleic acid molecule or said composition, for the manufacture of a medicament for preventing, treating, regressing, curing and/or delaying a disease or a condition wherein inflammation and/or coagulation and/or organ damage or failure occurs in an individual. Finally, the invention further relates to a method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of a disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur in an individual, the method comprising administering to said individual said nucleic acid molecule or said composition.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 7, 2021
    Assignee: APTAHEM AB
    Inventor: Luiza Anna Jedlina
  • A NUCLEIC ACID MOLECULE WITH ANTI-INFLAMMATORY AND ANTI-COAGULANT AND ORGAN-PROTECTIVE PROPERTIES
    Publication number: 20200268784
    Abstract: The invention relates to a nucleic acid molecule or a composition comprising said molecule for use as an anti-inflammatory and/or anti-coagulant and/or organ-protective medicament. The invention also relates to a use of said nucleic acid molecule or said composition, for the manufacture of a medicament for preventing, treating, regressing, curing and/or delaying a disease or a condition wherein inflammation and/or coagulation and/or organ damage or failure occurs in an individual. Finally, the invention further relates to a method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of a disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur in an individual, the method comprising administering to said individual said nucleic acid molecule or said composition.
    Type: Application
    Filed: October 3, 2018
    Publication date: August 27, 2020
    Applicant: APTAHEM AB
    Inventor: Luiza Anna JEDLINA
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9309516
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 12, 2016
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9309517
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 12, 2016
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9096857
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 4, 2015
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson